Dr. Geetha’s team focuses on renal diseases in patients with systemic vasculitis as well as BK virus nephropathy in patients who have undergone renal transplant. Our studies include clinical trials on the effectiveness of rituximab versus cyclosporine in treating idiopathic membranous nephropathy and a multinational study of belimumab with azathioprine for maintaining remission of granulomatosis with polyangiitis and microscopic polyangiitis. We also have conducted research on the treatment of ANCA vasculitis, particularly in kidney transplant patients.

Research in the Eric McCollum Lab focuses on pediatric pulmonary medicine, particularly pulmonary diseases among children in undeveloped, low-resource countries. We are taking part in the IMPACT trial, which looks at the impact of bubble continuous positive airway pressure (bCPAP) on the mortality of Malawian children with pneumonia.

The mission of the Elisseeff Lab is to engineer technologies to repair lost tissues. We aim to bridge academic research and technology discovery to treat patients and address clinically relevant challenges related to tissue engineering. To accomplish this goal we are developing and enabling materials, studying biomaterial structure-function relationships and investigating mechanisms of tissue development to practically rebuild tissues. The general approach of tissue engineering is to place cells on a biomaterial scaffold that is designed to provide the appropriate signals to promote tissue development and ultimately restore normal tissue function in vivo. Understanding mechanisms of cellular interactions (both cell-cell and cell-material) and tissue development on scaffolds is critical to advancement of the field, particularly in applications employing stem cells. Translation of technologies to tissue-specific sites and diseased environments is key to better design, understanding, and ultimately efficacy of tissue repair strategies. We desire to translate clinically practical strategies, in the form of biomaterials/medical devices, to guide and enhance the body's natural capacity for repair. To accomplish the interdisciplinary challenge of regenerative medicine research, we maintain a synergistic balance of basic and applied/translational research.

Utilizing a combination of tissue-based, cell-based, and molecular approaches, our research goals focus on abnormal telomere biology as it relates to cancer initiation and tumor progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype. In addition, our laboratories focus on cancer biomarker discovery and validation with the ultimate aim to utilize these novel tissue-based biomarkers to improve individualized prevention, detection, and treatment strategies.

Utilizing a combination of tissue-based, cell-based, and molecular approaches, our research goals focus on abnormal telomere biology as it relates to cancer initiation and tumor progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype. In addition, our laboratories focus on cancer biomarker discovery and validation with the ultimate aim to utilize these novel tissue-based biomarkers to improve individualized prevention, detection, and treatment strategies.

Wilmer Bioinformatics has been mainly focused on ocular informatics. Specifically, the group develops and applies bioinformatics approaches to study gene regulation and signaling networks, with particular but not exclusive attention to the mammalian retina. Understanding the molecular basis of tissue specific gene regulation and signaling will contribute to better prevention, diagnosis and treatment of retinal disease.

The mission of the laboratory of vestibular neurophysiology is to advance the understanding of how the body perceives head motion and maintains balance - a complex and vital function of everyday life. Although much is known about the vestibular part of the inner ear, key aspects of how the vestibular receptors perceive, process and report essential information are still mysterious. Increasing our understanding of this process will have tremendous impact on quality of life of patients with vestibular disorders, who often suffer terrible discomfort from dizziness and vertigo. The laboratory group's basic science research focuses on the vestibulo-ocular reflexes - the reflexes that move the eyes in response to motions of the head. They do this by studying the vestibular sensors and nerve cells that provide input to the reflexes; by studying eye movements in humans and animals with different vestibular disorders, by studying effects of electrical stimulation of vestibular sensors, and by using mathematical models to describe these reflexes. Researchers are particularly interested in abnormalities of the brain's inability to compensate for vestibular disorders.

Research in the Vestibular NeuroEngineering Lab (VNEL) focuses on restoring inner ear function through “bionic” electrical stimulation, inner ear gene therapy, and enhancing the central nervous system’s ability to learn ways to use sensory input from a damaged inner ear. VNEL research involves basic and applied neurophysiology, biomedical engineering, clinical investigation and population-based epidemiologic studies. We employ techniques including single-unit electrophysiologic recording; histologic examination; 3-D video-oculography and magnetic scleral search coil measurements of eye movements; microCT; micro MRI; and finite element analysis. Our research subjects include computer models, circuits, animals and humans. For more information about VNEL, click here. VNEL is currently recruiting subjects for two first-in-human clinical trials: 1) The MVI Multichannel Vestibular Implant Trial involves implantation of a “bionic” inner ear stimulator intended to partially restore sensation of head movement. Without that sensation, the brain’s image- and posture-stabilizing reflexes fail, so affected individuals suffer difficulty with blurry vision, unsteady walking, chronic dizziness, mental fogginess and a high risk of falling. Based on designs developed and tested successfully in animals over the past the past 15 years at VNEL, the system used in this trial is very similar to a cochlear implant (in fact, future versions could include cochlear electrodes for use in patients who also have hearing loss). Instead of a microphone and cochlear electrodes, it uses gyroscopes to sense head movement, and its electrodes are implanted in the vestibular labyrinth. For more information on the MVI trial, click here. 2) The CGF166 Inner Ear Gene Therapy Trial involves inner ear injection of a genetically engineered DNA sequence intended to restore hearing and balance sensation by creating new sensory cells (called “hair cells”). Performed at VNEL with the support of Novartis and through a collaboration with the University of Kansas and Columbia University, this is the world’s first trial of inner ear gene therapy in human subjects. Individuals with severe or profound hearing loss in both ears are invited to participate. For more information on the CGF166 trial, click here.

The Karakousis Lab is primarily focused on understanding the molecular basis of Mycobacterium tuberculosis persistence and antibiotic tolerance. A systems biology-based approach, including the use of several novel in vitro and animal models, in combination with transcriptional, proteomic, genetic, imaging, and computational techniques, is being used to identify host cytokine networks responsible for immunological control of M. tuberculosis growth, as well as M. tuberculosis regulatory and metabolic pathways required for bacillary growth restriction and reactivation. In particular, we are actively investigating the regulatory cascade involved in the mycobacterial stringent response. Another major focus of the lab is the development of host-directed therapies for TB, with the goal of shortening treatment and improving long-term lung function. Additional research interests include the development of novel molecular assays for the rapid diagnosis of latent TB infection and active TB disease, and for the detection of drug resistance.

Work in the Kristin Riekert Lab focuses on methods for improving health care quality and delivery, particularly among underserved and disadvantaged populations. Our research covers a range of important topics, including health beliefs, treatment adherence, doctor-patient communication, self-management interventions, mobile health initiatives, health disparities and patient-reported outcome methodology. We also work with the National Institutes of Health on multiple intervention trials focused on improving adherence and health outcomes in asthma, chronic kidney disease, cystic fibrosis (CF), sickle cell disease and secondhand smoke reduction.